Abstract 2125
Background
Brain metastasis (BM) is infrequently reported in patients (pts) with ovarian cancer (OC), with past studies reporting a rate of approximately 1%.1 This study estimated real-world incidence of BM in OC and assessed whether BRCA mutation (BRCAmut) increased risk of BM in OC pts.
Methods
This retrospective study included 4515 pts diagnosed with OC between Jan 1, 2011 and Jan 31, 2018 from the Flatiron Health database. This is a longitudinal, demographically and geographically diverse database derived from electronic health record data from over 265 cancer clinics and over 2 million active US cancer pts. A time-to-event analysis was conducted to assess whether pts with a known BRCAmut were more likely to develop BM compared with BRCA wild type (BRCAwt) pts.
Results
Of 4515 OC pts, 473 were BRCAmut, 1679 were BRCAwt, and 2363 had unknown BRCA status. A total of 46 pts (1%) had a diagnosis of BM subsequent to OC diagnosis. Of those with BRCAmut, 3% (14/473) developed BM; the BM rate was 0.6% (10/1679) for BRCAwt. The K-M estimate for the proportion of pts with BM within 5 years of diagnosis was 5.7% in the BRCAmut population compared with 1.4% in BRCAwt. BRCAmut pts had a significantly higher risk of developing BM compared with BRCAwt (HR 4.44 [95% CI 1.97, 10.00], P < 0.0001). A total of 281 OC pts also had a breast cancer (BC) diagnosis (186 developed BC prior to OC, 95 developed BC after OC diagnosis). After excluding these pts from the analysis, the HR for developing BM among BRCAmut pts vs. BRCAwt pts was 3.84 (95% CI 1.60, 9.22), P = 0.001. Multivariate models adjusting for other pt characteristics yielded similar HRs. Among pts who developed BM, median time from OC diagnosis to BM diagnosis was 27 months in BRCAmut pts and 35 months in BRCAwt. Median survival after diagnosis of BM was 7.16 months (95% CI 3.48, 16.49). Overall survival after BM did not differ significantly by BRCA status.
Conclusions
OC pts with BRCAmut seem to have a higher risk of developing BM. Further research is needed to confirm these findings and better understand potential mechanisms and implications for management, given the poor prognosis in pts who develop BM. 1Pectasides et al. The Oncologist 2006;11:252–260.
Clinical trial identification
Legal entity responsible for the study
Tesaro, Inc.
Funding
Tesaro, Inc.
Editorial Acknowledgement
Editorial support, funded by Tesaro, Inc. (Waltham, MA, USA) and coordinated by Michael Stillman PhD of Tesaro, Inc., was provided by Dena McWain of Ashfield Healthcare Communications (Middletown, CT, USA).
Disclosure
E. Ratner: Advisory board: Tesaro Inc. M. Bala, M. Louie-Gao, S. Hazard: Employment and stock and other ownership interests in Tesaro Inc. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract